CPI203 inhibits BRD4 in vitro and in cells, while does not affect BRD4 kinase activity in vitro.CPI203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 ¦ÌM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, lenalidomide and CPI203, by targeting IRF4 and MYC, efficiently activates the cell death program in MCL cells resistant to bortezomib

June 21, 2017

prudect name : CPI203 inhibits BRD4 in vitro and in cells, while does not affect BRD4 kinase activity in vitro.CPI203 exerts a cytostatic effect in all the 9 MCL cell lines analyzed with GI50 ranging from 0.06 to 0.71 ¦ÌM, with low cytotoxicity in normal PBMCs from healthy donors. Furthermore, lenalidomide and CPI203, by targeting IRF4 and MYC, efficiently activates the cell death program in MCL cells resistant to bortezomib
CPI 203

Synonyms: CAS NO: 1446144-04-2Molecular Formula: C₁₉H₁₈ClN₅OSMolecular Weight: 399.90Purity: 98% minSolubility: In DMSOStorage: −20°C 2 years

stearoyl-CoA desaturase (SCD) inhibitor References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508204